fbpx
June 6, 2022

Enhertu Benefit in HER2-Low Breast Cancer: ‘Practice Changing’ Enhertu Benefit in HER2-Low Breast Cancer: ‘Practice Changing’

CHICAGO — Breast cancer patients with low levels of HER2 expression, previously considered untreatable with HER2-targeted therapies, benefited from the anti-HER2 antibody drug conjugate trastuzumab deruxtecan. The therapy […]
June 6, 2022

Teclistamab Shows ‘Promising’ Activity in R/R Multiple Myeloma Teclistamab Shows ‘Promising’ Activity in R/R Multiple Myeloma

A weekly subcutaneous dose of teclistamab resulted in high response rates among adults with relapsed or refractory multiple myeloma, based on data from 165 patients in […]
June 6, 2022

Physicians React: Burnout Rates Are Alarming, so Who Should Drive Change? Physicians React: Burnout Rates Are Alarming, so Who Should Drive Change?

When physicians lament they feel burned out at work, what exactly do they mean? Here’s how one doctor describes conditions that lead to burnout: “I barely […]
June 6, 2022

EULAR RA Recommendations: Start Methotrexate, Steroids First EULAR RA Recommendations: Start Methotrexate, Steroids First

COPENHAGEN – New recommendations for the management of rheumatoid arthritis from the European Alliance of Associations for Rheumatology suggest starting short-term methotrexate and glucocorticoids when starting or […]
June 6, 2022

Sacituzumab a ‘Step Forward’ in Breast Cancer Unmet Need Sacituzumab a ‘Step Forward’ in Breast Cancer Unmet Need

An antibody drug conjugate that targets a cell-surface antigen found on most breast and bladder cancers demonstrated improved progression-free survival over standard chemotherapy in patients with […]
June 5, 2022

First-Line Treatment in Newly Diagnosed Multiple Myeloma First-Line Treatment in Newly Diagnosed Multiple Myeloma

New results from a trial in patients with newly diagnosed multiple myeloma offer some answers to questions about which treatment route to choose. The trial, known […]
June 5, 2022

International Trial Finds Best Regimen for Ewing Sarcoma International Trial Finds Best Regimen for Ewing Sarcoma

High-dose ifosfamide has shown superior survival benefit over three other chemotherapy regimens for patients with recurring or refractory primary Ewing sarcoma (RR-ES) in the practice-changing rEECur […]
June 5, 2022

Panitumumab Beats Bevacizumab in Left-Sided mCRC Panitumumab Beats Bevacizumab in Left-Sided mCRC

A suspicion from retrospective data has now been confirmed by a prospective clinical trial: adding panitumumab (Vectibix) to standard chemotherapy in left-sided RAS wild-type metastatic colorectal […]
June 5, 2022

Weekly Dulaglutide Promising in Youth With Type 2 Diabetes Weekly Dulaglutide Promising in Youth With Type 2 Diabetes

Another glucagon-like peptide-1 (GLP1) agonist, dulaglutide (Trulicity, Lilly), is poised to be a new option for glycemic control in youth ages 10 to 18 with type […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592593594595596597598599600601602603604605606607608609610611612613614615616617618619620621622623624625626627628629630631632633634635636637638639640641642643644645646647648649650651652653654655656657658659660661662663664665666667668669670671672673674675676677678679680681682683684685686687688689690691692693694695696697698699700701702703704705706707708709710711712713714715716717718719720721722723724725726727728729730731732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792793794795796797798799800801802803804805806807808809810811812813814815816817818819820821822823824825826827828829830831832833834835836837838839840841842843844845846847848849850851852853854855856857858859860861862863864865866867868869870871872873874875876877878879880881882883884885886887888889890891892893894895896897898899900901902903904905906907908909910911912913914915916917918919920921922923924925926927928929930931932933934935936937938939940941942943944945946947948
Next page
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0